Cytocast

Associate Sponsor

Cytocast is a TechBio company building the CYTOCAST DIGITAL TWIN Platform™ for mechanistic drug safety prediction, helping pharma teams identify side-effect risks early by modeling how compounds perturb targets, pathways, and human tissues to enable more informed decisions. 

___________________________________________________________________________________________________________________

Cytocast is a TechBio company building the CYTOCAST DIGITAL TWIN Platform™, a mechanistic drug safety intelligence platform designed to redefine preclinical safety assessment. The platform combines systems biology, artificial intelligence, and high-performance molecular simulation to predict off-target interactions and clinically relevant side effects early in drug development. 

Unlike conventional AI approaches that rely primarily on chemical similarity, Cytocast applies a biorealistic, simulation-driven methodology. It models how compounds interact with both intended targets and off-target proteins, and how these perturbations propagate through protein complexes, signaling pathways, and tissues. This enables a mechanistic chain of insight: compound → targets & off-targets → complex & pathway perturbations → clinical side effects. The result is not just a prediction, but a traceable and interpretable understanding of risk. 

By integrating cellular biophysics and proteome-scale modeling, the platform captures system-level biological responses in a fully in-silico environment. This allows pharmaceutical and biotech teams to identify and understand safety risks earlier, guide medicinal chemistry optimization, and make more informed go/no-go decisions before costly preclinical and clinical stages. 

Cytocast operates within a broader industry shift from empirical, late-stage safety assessment toward predictive, model-based approaches aligned with emerging New Approach Methodologies (NAMs) and in silico R&D workflows. Its safety-first perspective complements efficacy-driven discovery platforms, adding a critical decision layer focused on de-risking. 

Key differentiators include mechanistic (not black-box) predictions, system-level modeling across tissues, clinically interpretable outputs, and a focus on human-relevant safety insights beyond traditional toxicity proxies. 

By revealing drug safety risks early, Cytocast enables teams to advance the best candidates with greater confidence, improving R&D efficiency and reducing late-stage failure risk. 

 
 
Products 

SCREENER 

The CYTOCAST DIGITAL TWIN Platform™ is deployed through three integrated products: Screener, Optimizer, and Nominator, forming a continuous safety decision layer across drug development. Cytocast Screener™ is the entry point of this system, designed for early discovery. 

Cytocast Screener™ focus — Early Discovery 

  

Cytocast Screener™ is designed for high-throughput triage of large compound libraries. 

It enables: 

- Early identification of off-target liabilities 

- Rapid safety filtering before synthesis or in-depth testing 

- Prioritization of compounds with more favorable safety profiles 

  

Cytocast Screener™ allows teams to: 

  - Remove high-risk compounds before costly experiments 

- Focus resources on viable candidates 

- Introduce safety as an early design constraint 

  

Overview   

Cytocast is building a digital twin platform for predicting clinically relevant drug side effects early in development, shifting safety from reactive management to proactive design. 

  Despite advances in drug discovery, late-stage failures are still largely driven by safety risks that originate from off-target interactions and downstream biological effects not sufficiently understood early on. While adverse events are generally well managed, this happens predominantly after they emerge. As a result, safety remains reactive rather than engineered proactively. 

  

The CYTOCAST DIGITAL TWIN Platform™ addresses this gap by introducing an upstream safety intelligence layer that enables teams to anticipate, interpret, and act on safety risks before they materialize. 

  

How it works 

  At its core, the platform links compound structure to clinical phenotype through a mechanistic chain: 

  compound → targets & off-targets → protein complexes & pathways → clinically relevant side effects 

  

Powered by machine learning, systems biology, and high-performance computing, the DIGITAL TWIN Cell™ simulates perturbations across: 

- 7,700+ proteins 

- 29 tissue types 

- 500+ clinically observed side effects 

  

Outputs are probabilistic, uncertainty-aware, and stratified into Gold, Silver, and Bronze tiers. 

 

 

OPTIMIZER 

The CYTOCAST DIGITAL TWIN Platform™ consists of three integrated products: Screener, Optimizer, and Nominator, supporting safety decisions across the pipeline. Cytocast Optimizer™ operates at the lead optimization stage. 

Cytocast Optimizer™ focus — Lead Optimization 

  

Cytocast Optimizer™ provides comparative safety assessment across candidate series. 

It enables: 

- Ranking of compounds based on specific side-effect risks 

- Mechanistic understanding of why differences occur 

- Selection of candidates with the best overall safety profile 

  

Cytocast Optimizer™ allows teams to: 

- Make safety-informed trade-offs between candidates 

- Guide chemistry and design decisions 

- Reduce downstream risk through better selection 

  

Overview 

  Cytocast is building a digital twin platform for predicting clinically relevant drug side effects early in development, shifting safety from reactive management to proactive design. 

  Despite advances in drug discovery, late-stage failures are still largely driven by safety risks that originate from off-target interactions and downstream biological effects not sufficiently understood early on. While adverse events are generally well managed, this happens predominantly after they emerge. As a result, safety remains reactive rather than engineered proactively. 

  

The CYTOCAST DIGITAL TWIN Platform™ addresses this gap by introducing an upstream safety intelligence layer that enables teams to anticipate, interpret, and act on safety risks before they materialize. 

  

How it works 

  At its core, the platform links compound structure to clinical phenotype through a mechanistic chain: 

  compound → targets & off-targets → protein complexes & pathways → clinically relevant side effects 

  

Powered by machine learning, systems biology, and high-performance computing, the DIGITAL TWIN Cell™ simulates perturbations across: 

- 7,700+ proteins 

- 29 tissue types 

- 500+ clinically observed side effects 

  

Outputs are probabilistic, uncertainty-aware, and stratified into Gold, Silver, and Bronze tiers. 

 

NOMINATOR 

The CYTOCAST DIGITAL TWIN Platform™ integrates three products: Screener, Optimizer, and Nominator, to support safety decisions from discovery to IND. Cytocast Nominator™ provides decision-grade safety insight at the final preclinical stage. 

Cytocast Nominator™ focus — IND-Enabling 

  

Cytocast Nominator™ delivers comprehensive, decision-grade safety profiles for final candidate selection. 

It enables: 

- Holistic evaluation of lead and backup candidates 

- Mechanistic interpretation of safety risks 

- Contextualization against known compounds and profiles 

  

Cytocast Nominator™ allows teams to: 

- Make confident go/no-go decisions 

- Strengthen IND readiness with mechanistic evidence 

- Support internal and external decision-making with clear safety narratives 

  

Overview 

  

Cytocast is building a digital twin platform for predicting clinically relevant drug side effects early in development, shifting safety from reactive management to proactive design. 

  

Despite advances in drug discovery, late-stage failures are still largely driven by safety risks that originate from off-target interactions and downstream biological effects not sufficiently understood early on. While adverse events are generally well managed, this happens predominantly after they emerge. As a result, safety remains reactive rather than engineered proactively. 

  

The CYTOCAST DIGITAL TWIN Platform™ addresses this gap by introducing an upstream safety intelligence layer that enables teams to anticipate, interpret, and act on safety risks before they materialize. 

  

How it works 

  

At its core, the platform links compound structure to clinical phenotype through a mechanistic chain: 

  

compound → targets & off-targets → protein complexes & pathways → clinically relevant side effects 

  

Powered by machine learning, systems biology, and high-performance computing, the DIGITAL TWIN Cell™ simulates perturbations across: 

- 7,700+ proteins 

- 29 tissue types 

- 500+ clinically observed side effects 

  

Outputs are probabilistic, uncertainty-aware, and stratified into Gold, Silver, and Bronze tiers. 
 

 

 

Product description (CYTOCAST DIGITAL TWIN Platform) --- this was not used eventually 

 

SHORT:  

Cytocast provides an AI- and simulation-powered digital twin platform for predicting clinically relevant drug side effects early in development. The platform supports critical R&D decisions from early screening to IND-enabling candidate selection. 

 
 
LONG:  

Cytocast is building a digital twin platform for predicting clinically relevant drug side effects early in development, shifting safety from reactive management to proactive design.  

Despite advances in drug discovery, late-stage failures are still largely driven by safety risks that originate from off-target interactions and downstream biological effects not sufficiently understood early on. While adverse events are generally well managed, this happens predominantly after they emerge. As a result, safety remains a reactive process rather than a proactively engineered one. This creates a fundamental gap: drug safety is handled once it manifests, but is not systematically predicted and shaped at the stage when it is still most tractable. 

The CYTOCAST DIGITAL TWIN Platform™ addresses this gap by introducing an upstream safety intelligence layer that enables teams to anticipate, interpret, and act on safety risks before they materialize.  

At its core, the platform links compound structure to clinical phenotype through a transparent, mechanistic chain:  

compound → targets & off-targets → protein complexes & pathways → clinically relevant side effects  

The platform integrates machine learning, systems biology, and high-performance computing to simulate how drug-induced perturbations propagate through biological systems. Unlike black-box AI models, Cytocast provides interpretable, mechanism-linked outputs that enable both prediction and understanding of safety risks.  

  

At its core is the DIGITAL TWIN Cell™, a whole-cell, multi-tissue simulation environment that models perturbations across:  

- 7,700+ proteins   

- 29 tissue types   

- 500+ clinically observed side effects (MedDRA PT)   

  

Predictions are probabilistic and uncertainty-aware, stratified into Gold, Silver, and Bronze tiers, enabling prioritization based on confidence and decision context.  

  

The platform is deployed through three integrated products, each aligned with a critical stage of drug development:  

  

Cytocast Screener™ — Early Discovery  

  

Designed for high-throughput triage of large compound libraries, Screener™ enables rapid identification of safety liabilities before synthesis or downstream testing. Supports: Early elimination, prioritisation, and safer candidate selection.  

  

Cytocast Optimizer™ — Lead Optimization  

  

Optimizer™ provides comparative safety assessment across shortlisted candidates. It enables filtering and ranking based on selected side effects. Supports: Hit-to-lead progression, series selection, and cross-functional decision-making.  

  

Cytocast Nominator™ — IND-Enabling  

  

Nominator™ delivers a comprehensive, decision-grade safety profile for lead and backup selection. It contextualizes candidates against existing and pipeline compounds, providing mechanistic narratives and clinically relevant risk interpretation. Supports: Candidate nomination, IND preparation, and portfolio-level justification.  

  

Value and differentiation  

  

Cytocast uniquely combines:  

- Mechanistic, system-level modeling (not chemistry-only or black-box AI)   

- Clinically interpretable outputs based on observed side effects  

- Traceability from molecular interaction to clinical outcome   

- Confidence-aware predictions supporting real decision-making   

  

This enables pharmaceutical and biotech teams to:  

- anticipate safety risks earlier   

- reduce late-stage failures   

- make more informed portfolio decisions   

- integrate predictive safety into standard R&D workflows   

  

Why now  

Regulatory and industry momentum toward New Approach Methodologies (NAMs) and model-informed drug development (MIDD) is accelerating the need for predictive, human-relevant safety tools.  Cytocast aligns with this shift, providing a mechanistic, interpretable approach that allows teams not just to manage adverse events, but to shape where the safety–efficacy balance will land, while it is still possible to change it. 

website